GIP and metabolic dysfunction-associated steatohepatitis: ,33 There is evidence, for example, of MASH histological benefits from four classes of pharmacological treatments, some of which are used for obesity and/or T2D, including peroxisome proliferator-activated receptor agonists,34 glucagon-like peptide-1 receptor (GLP-1R) agonists,35 dual glucose-dependent insulinotropic polypeptide-GLP-1R agonists,36 and triple agonists,37,38 though none are currently approved as MASH specific treatments.